Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Continuous infusion therapy with very high purity von Willebrand factor concentrate in patients with severe von Willebrand disease.

Smith MP, Rice KM, Bromidge ES, Lawn M, Beresford-Webb R, Spence K, Khair K, Hann I, Savidge GF.

Blood Coagul Fibrinolysis. 1997 Jan;8(1):6-12.

PMID:
9105631
2.

Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.

Lubetsky A, Schulman S, Varon D, Martinowitz U, Kenet G, Gitel S, Inbal A.

Thromb Haemost. 1999 Feb;81(2):229-33.

PMID:
10063997
3.

Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.

Favaloro EJ, Lloyd J, Rowell J, Baker R, Rickard K, Kershaw G, Street A, Scarff K, Barrese G, Maher D, McLachlan AJ.

Thromb Haemost. 2007 Jun;97(6):922-30.

PMID:
17549293
4.

Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity.

Goudemand J, Mazurier C, Marey A, Caron C, Coupez B, Mizon P, Goudemand M.

Br J Haematol. 1992 Feb;80(2):214-21.

PMID:
1550779
5.

Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study.

Mannucci PM, Chediak J, Hanna W, Byrnes J, Ledford M, Ewenstein BM, Retzios AD, Kapelan BA, Schwartz RS, Kessler C; Alphanate Study Group.

Blood. 2002 Jan 15;99(2):450-6.

PMID:
11781224
6.

von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.

Gill JC, Shapiro A, Valentino LA, Bernstein J, Friedman C, Nichols WL, Manco-Johnson M.

Haemophilia. 2011 Nov;17(6):895-905. doi: 10.1111/j.1365-2516.2011.02534.x. Epub 2011 Apr 27.

PMID:
21535320
7.

Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate).

Auerswald G, Eberspächer B, Engl W, Güthner C, Koksch M, Kreuz W, Nimtz A, Pindur G, Scheel H, Schreiber JD, Siekmann J, Turecek PL, Wolf HH.

Semin Thromb Hemost. 2002 Apr;28(2):203-14.

PMID:
11992243
8.
9.

Biological effects of a S/D-treated, very high purity, von Willebrand factor concentrate in five patients with severe von Willebrand disease.

Meriane F, Zerhouni L, Djeha N, Goudemand M, Mazurier C.

Blood Coagul Fibrinolysis. 1993 Dec;4(6):1023-9.

PMID:
8148475
10.

Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients.

Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, Rothschild C, Berntorp E, Henriet C, Tellier Z, Bridey F, Mannucci PM.

J Thromb Haemost. 2007 Jun;5(6):1115-24.

11.

Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.

Windyga J, von Depka-Prondzinski M; European Wilate® Study Group.

Thromb Haemost. 2011 Jun;105(6):1072-9. doi: 10.1160/TH10-10-0631. Epub 2011 Mar 24.

PMID:
21437358
12.

In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease.

Turecek PL, Gritsch H, Pichler L, Auer W, Fischer B, Mitterer A, Mundt W, Schlokat U, Dorner F, Brinkman HJ, van Mourik JA, Schwarz HP.

Blood. 1997 Nov 1;90(9):3555-67.

PMID:
9345039
13.
14.

Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience.

Lubetsky A, Martinowitz U, Luboshitz J, Kenet G, Keller N, Tamarin I, Inbal A.

Haemophilia. 2002 Sep;8(5):622-8.

PMID:
12199669
15.

Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.

Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, Manzato F, Bertuzzo D, Gandini G.

Haematologica. 2003 Nov;88(11):1279-83.

16.
17.

Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.

Federici AB, Baudo F, Caracciolo C, Mancuso G, Mazzucconi MG, Musso R, Schinco PC, Targhetta R, Mannuccio Mannucci P.

Haemophilia. 2002 Nov;8(6):761-7.

PMID:
12410644
19.

von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.

Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM; HAEMATE P Surgical Study Group.

J Thromb Haemost. 2007 Jul;5(7):1420-30. Epub 2007 Apr 16.

20.

Clinical management of patients with von Willebrand's disease with a VHP vWF concentrate: the French experience.

Goudemand J, Negrier C, Ounnoughene N, Sultan Y.

Haemophilia. 1998;4 Suppl 3:48-52.

PMID:
10028319

Supplemental Content

Support Center